tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 6 are a HOLD (2.93%), 198 are a BUY (96.59%), 1 are a SELL (0.49%).
Analyst Chad Messer, currently employed at LAKE STREET, carries an average stock price target met ratio of 42.98% that have a potential upside of 48.35% achieved within 394 days. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 404 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 25-Jun-2026.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/6/2015. The price target of $104 was fulfilled within 12 days with a profit of $38.72 (59.31%) receiving and performance score of 49.43.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-Jan-2024
$37
$39
18 days ago
(07-Oct-2026)
13/15 (86.67%)
$5.21 (16.39%)
93
Buy Since 31-Mar-2026
$50
$13 (35.14%)
$46
1 months 4 days ago
(21-Sep-2026)
3/5 (60%)
$16.05 (47.28%)
72
Hold Since 01-Dec-2022
$34
$-3 (-8.11%)
$31
2 months 18 days ago
(07-Aug-2026)
11/12 (91.67%)
$1.73 (5.36%)
113
Buy Since 05-Mar-2026
$52
$15 (40.54%)
$46
2 months 24 days ago
(31-Jul-2026)
1/3 (33.33%)
$21.98 (73.22%)
215
Buy Since 24-Feb-2025
$55
$18 (48.65%)
$52
2 months 25 days ago
(30-Jul-2026)
0/11 (0%)
$22.25 (67.94%)
Which stock is Chad Messer most bullish on?
What Year was the first public recommendation made by Chad Messer?
